Leading Radiology Forward
(Procedures in Thousands)
($ in Millions)
Proven Track Record of EBITDA Growth and Cash Flow Generation
Over the past 11 years, RadNet has had a consistent track record of achieving profitable growth and generating significant cash flow
COVID-19 had a temporary impact during 2020
Net Revenue
Net Revenue
ICO VID Impact
$1,400
Reported Adjusted EBITDA
■Net Revenue CO VID Impact
$1,275
$185
$1,200
$1,000
$800
'09-'21E CAGR: 8.2%
$1,200
$1,154
$175
$170
$128
$885 $922
$975
$155
$810
$703 $718
$647
$585
$600
$495 $519
$400
$200
$-
H
($ in Millions)
'09-'21E CAGR: 4.8%
$164
$143 $144
$31
$135
$133
$127
$115
$116 $114 $113
$122
$106 $106
$95
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021E
$75
Procedure Volumes
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021E
10,000
Procedures COVID Impact
8,388
8,495
7,886
8,000
'09-'21E CAGR: 7.6%
6,280
7,393
6,937
7,116
1,521
6,000
5,526
4,961
4,587
4,122
4,000
3,544
3,679
2,000
0
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021E
Source: Company Filings and Presentation.
Note: 2021E illustrated at midpoint of the guidance ranges. Volumes include consolidated and non-consolidated Joint Ventures.
RadNet.
Leading Radiology Forward
8View entire presentation